SCHEMBL4900758

SCHEMBL4900758

Cc1cnc(-c2cccc(Nc3ccccn3)n2)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.58
SRC P12931 1/20 0.46
CDK2 P24941 1/20 0.46
ZAP70 P43403 1/20 0.46
SYK P43405 1/20 0.46
NPC1 O15118 5/20 0.45
RAB9A P51151 5/20 0.45
KMT2A Q03164 5/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
TP53 P04637 2/20 0.45
TDP1 Q9NUW8 2/20 0.45
KDM4E B2RXH2 2/20 0.45
LMNA P02545 2/20 0.45
ALOX15 P16050 1/20 0.45
TSHR P16473 1/20 0.45
ALOX12 P18054 1/20 0.45
HTT P42858 1/20 0.45
KLF5 Q13887 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MEN1 O00255 4/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4901229 0.83 KDR (0.58) KDRNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL4896924 0.83 KMT2A (0.42) KDRSRCZAP70SYKNPC1
SCHEMBL4900827 0.83 KDR (0.43) KDRCDK2NPC1RAB9AKMT2A
SCHEMBL30606304 0.78 ALDH1A1 (0.58) KDRSRCCDK2ZAP70SYK
SCHEMBL12116515 0.78 ALDH1A1 (0.58) KDRSRCCDK2ZAP70SYK
SCHEMBL20919346 0.78 KMT2A (0.57) KDRNPC1RAB9AKMT2ASMN1; SMN2
SCHEMBL16844384 0.78 SYK (0.44) KDRSRCCDK2ZAP70SYK
SCHEMBL4899105 0.78 CCNA2 (0.46) CDK2
SCHEMBL14673927 0.77 SLC2A1 (0.54) KDRSYKNPC1RAB9AKMT2A
SCHEMBL4895751 0.77 CCNA2 (0.48) CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators ICAGEN, INC. (US) 2008-05-08 US disclosed
EP-1737852-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS Icagen, Inc. (US) 2007-01-03 EP disclosed
WO-2005100349-A2 POLYCYCLIC PYRIDINES AS POTASSIUM ION CHANNEL MODULATORS ICAGEN, INC. (US) 2005-10-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108600-A1 Polycyclic Pyridines as Potassium Ion Channel Modulators KCNJ2, KCNH2, KCNQ1 KDR 3367/4885SRC 4155/4885CDK2 3182/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.